NFE2L2 and obesity disorder: Moreover, Shin S. et al. demonstrated that treatment with CDDO imidazolide, a potent Nrf2 activator, could prevent high-fat diet-induced increases in body weight, adipose mass, and hepatic lipid accumulation via increasing oxygen consumption and energy expenditure, and decreasing food intake in wild-type mice, but not in Nrf2-disrupted mice, which indicates that activation of the Nrf2 pathway prevents obesity [84].